Abo Bibliothek: Guest
Digitales Portal Digitale Bibliothek eBooks Zeitschriften Referenzen und Berichte Forschungssammlungen
Critical Reviews™ in Oncogenesis
SJR: 0.946 SNIP: 0.503 CiteScore™: 2

ISSN Druckformat: 0893-9675
ISSN Online: 2162-6448

Critical Reviews™ in Oncogenesis

DOI: 10.1615/CritRevOncog.v17.i2.20
pages 145-159

Src Kinase Inhibitors: Promising Cancer Therapeutics?

Helen Creedon
Edinburgh Cancer Research Centre, Institute of Genetics & Molecular Medicine, University of Edinburgh
Valerie G . Brunton
Edinburgh Cancer Research Centre, Institute of Genetics & Molecular Medicine, University of Edinburgh

ABSTRAKT

Src is the cellular counterpart of the first identified viral oncogene v-Src. It forms part of a large family of nonreceptor tyrosine kinases that have been extensively studied over the last few decades. This has led to the realization that Src can regulate a number of signaling pathways that impact on the behavior of tumor cells, including proliferation, survival, migration, invasion, and angiogenesis. There are currently four Src inhibitors (dasatinib, saracatinib, bosutinib, and KX01) in clinical development, and although there is a plethora of information on their activity in preclinical models their clinical efficacy has been disappointing. Here we review the current status of the Src inhibitors and highlight the difficulties involved in assessing these therapeutics in the clinical setting. In the future it will be important to combine our knowledge of basic Src biology with the use of appropriate preclinical models to aid the design of clinical trials. Taking this integrated approach will hopefully help to realize the true potential of Src kinase inhibitors.


Articles with similar content:

Epidermal Growth Factor Receptor Tyrosine Kinase: A Potential Target in Treatment of Non-Small-Cell Lung Carcinoma
Journal of Environmental Pathology, Toxicology and Oncology, Vol.36, 2017, issue 2
Niranjali Devaraj, Venugopal Vinod Prabhu
Utilization of Nuclear Matrix Proteins for Cancer Diagnosis
Critical Reviews™ in Eukaryotic Gene Expression, Vol.6, 1996, issue 2-3
Joseph V. Briggman, Ying-Jye Wu, Susan K. Keesee, Gregory Thill
Diverse Signaling Pathways and Current Status of Molecular Targeted Treatments for Hepatocellular Carcinoma
Critical Reviews™ in Eukaryotic Gene Expression, Vol.27, 2017, issue 4
Ali Sharif, Wafa Majeed, Bushra Akhtar, Muhammad Furqan Akhtar, Faqir Muhammad
Twenty Years on: What Do We Really Know about Ewing Sarcoma and What Is the Path Forward?
Critical Reviews™ in Oncogenesis, Vol.20, 2015, issue 3-4
Elizabeth R. Lawlor, Poul H. Sorensen
Kruppel-Like Factor 4: From Physiological Functions to Tumor Therapy
Forum on Immunopathological Diseases and Therapeutics, Vol.7, 2016, issue 1-2
Peng Li, Ruocong Zhao, Yunxin Lai